2. Metabolic Enzyme/Protease Neuronal Signaling MAPK/ERK Pathway Apoptosis Autophagy
  3. Phosphatase Cholinesterase (ChE) p38 MAPK Apoptosis Autophagy
  4. Neoeriocitrin

Neoeriocitrin is a Naringin (HY-N0153) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease.

For research use only. We do not sell to patients.

Neoeriocitrin

Neoeriocitrin Chemical Structure

CAS No. : 13241-32-2

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Neoeriocitrin:

Neoeriocitrin Related Antibodies

Top Publications Citing Use of Products

View All Cholinesterase (ChE) Isoform Specific Products:

View All Isoforms
AChE BChE

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Neoeriocitrin is a Naringin (HY-N0153) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease[1][2][3][4].

IC50 & Target[1]

AChE

 

In Vitro

Neoeriocitrin (2-20 μg/mL; 72 h) modulates MC3T3-E1 cell proliferation in a dose-dependent manner[1].
Neoeriocitrin (2-20 μg/mL; 5 days) increases MC3T3-E1 cell ALP activity in a dose-dependent manner[1].
Neoeriocitrin (2 μg/mL; 4-8 days) upregulates expression of osteogenic marker genes Runx2, COL I, and OCN in MC3T3-E1 cells[1].
Neoeriocitrin (2 μg/mL; 5 days) partially rescues PD98059 (HY-12028)-induced inhibition of ALP activity in MC3T3-E1 cells[1].
Neoeriocitrin (2 μg/mL; 4-8 days) partially rescues PD98059-induced downregulation of COL I and OCN mRNA expression in MC3T3-E1 cells[1].
Neoeriocitrin (2.5-200 μM; 1-14 days) significantly and sustainably promotes the proliferation of human dental pulp stem cells[2].
Neoeriocitrin (2.5-10 μM; 7-21 days) enhances the osteogenic differentiation of human dental pulp stem cells, as measured by increased osteogenic gene and protein expression, alkaline phosphatase activity, and mineralization[2].
Neoeriocitrin (100 μM; 1 h) directly binds to Beclin1 in human dental pulp stem cells, as identified by increased thermal stability of Beclin1 in thermal proteome profiling[2].
Neoeriocitrin (2.5-10 μM; 48 h) induces autophagy in human dental pulp stem cells, as measured by reduced P62 levels, increased LC3-II/I ratio, enhanced autophagosome formation, and increased autophagosome number detected via transmission electron microscopy[2].
Neoeriocitrin (5 μM) requires Beclin1 as a critical mediator for its induced autophagy and osteogenic differentiation in human dental pulp stem cells, as Beclin1 knockdown attenuates and Beclin1 overexpression amplifies Neoeriocitrin's effects[2].
Neoeriocitrin (5 μM; 3-12 h) stabilizes Beclin1 protein in human dental pulp stem cells by inhibiting ubiquitin-mediated proteasomal degradation, thereby extending Beclin1 half-life[2].
Neoeriocitrin (6×104 μM; 2 h pre-incubation, 22 h co-incubation with Aβ25-35) protects Aβ25-35 (HY-P0128)-damaged PC12 cells by reducing apoptosis, upregulating ERβ expression, inhibiting P38 protein phosphorylation, and improving cholinergic system function[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Neoeriocitrin Related Antibodies

Cell Proliferation Assay[1]

Cell Line: MC3T3-E1 preosteoblast cells
Concentration: 2, 4, 8, 10, 20 μg/mL
Incubation Time: 72 h
Result: Increased proliferation rate at 2 and 4 μg/mL.
Decreased proliferation rate at 8-10 μg/mL.

Real Time qPCR[1]

Cell Line: MC3T3-E1 preosteoblast cells
Concentration: 2 μg/mL
Incubation Time: 4 days (Runx2 and COL I); 8 days (OCN)
Result: Increased Runx2, COL I and OCN mRNA expression.

Cell Proliferation Assay[2]

Cell Line: human dental pulp stem cells (hDPSCs)
Concentration: .5, 5, 10,
25, 50, 100, and 200 μM
Incubation Time: , 3, 5, 7, and 14 days
Result: Produced a sustained, significant enhancement of hDPSCs proliferation from day 5 onwards at 2.5, 5, and 10 μM, compared to control or higher concentrations.
Stimulated proliferation in the first 3 days at concentrations below 200 μM.

Cell Differentiation Assay[2]

Cell Line: human dental pulp stem cells (hDPSCs)
Concentration: 2.5,
5, and 10 μM
Incubation Time: 7 days (ALP staining, gene/protein expression); 21 days (alizarin red staining)
Result: Most significantly upregulated osteogenesis-related mRNA (Collagen I, ALP, OPN, Runx2) and protein (Collagen I, ALP, OPN, Runx2) expression.
Showed the largest positive area percentage in ALP staining at 7 days with 5 μM.
Showed the highest mineralization in alizarin red staining at 21 days with 5 μM.

Cell Autophagy Assay[2]

Cell Line: human dental pulp stem cells (hDPSCs)
Concentration: 2.5,
5, and 10 μM
Incubation Time: 48 h
Result: Significantly reduced P62 protein levels and increased the LC3-II/I ratio at 2.5 and 5 μM.
Showed a diminished, non-significant effect on P62 at 10 μM.
Increased the number of yellow (RFP+GFP+) puncta (autophagosomes) and the number of autophagosomes visible via TEM at 5 μM, compared to control.
In Vivo

Neoeriocitrin (P3 hDPSCs cultured with Neoeriocitrin for 5 days and then combined with Bio-Oss bone grafting material at a seeding density of 1 × 107 cells) significantly enhances new bone formation in rat critical-sized calvarial defects, with increased autophagy marker expression (Beclin1, LC3) and reduced P62 in regenerating bone tissue[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

596.53

Formula

C27H32O15
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C1C2=C(O)C=C(O[C@H]3[C@@H]([C@H]([C@H](O)[C@@H](CO)O3)O)O[C@@]4([H])[C@@H]([C@@H]([C@@H](O)[C@H](C)O4)O)O)C=C2O[C@H](C5=CC(O)=C(O)C=C5)C1
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (167.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.6764 mL 8.3818 mL 16.7636 mL
5 mM 0.3353 mL 1.6764 mL 3.3527 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.97%

SDS (252 KB)

COA (253 KB) RP-HPLC (255 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.6764 mL 8.3818 mL 16.7636 mL 41.9090 mL
5 mM 0.3353 mL 1.6764 mL 3.3527 mL 8.3818 mL
10 mM 0.1676 mL 0.8382 mL 1.6764 mL 4.1909 mL
15 mM 0.1118 mL 0.5588 mL 1.1176 mL 2.7939 mL
20 mM 0.0838 mL 0.4191 mL 0.8382 mL 2.0955 mL
25 mM 0.0671 mL 0.3353 mL 0.6705 mL 1.6764 mL
30 mM 0.0559 mL 0.2794 mL 0.5588 mL 1.3970 mL
40 mM 0.0419 mL 0.2095 mL 0.4191 mL 1.0477 mL
50 mM 0.0335 mL 0.1676 mL 0.3353 mL 0.8382 mL
60 mM 0.0279 mL 0.1397 mL 0.2794 mL 0.6985 mL
80 mM 0.0210 mL 0.1048 mL 0.2095 mL 0.5239 mL
100 mM 0.0168 mL 0.0838 mL 0.1676 mL 0.4191 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Neoeriocitrin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Neoeriocitrin13241-32-2PhosphataseCholinesterase (ChE)p38 MAPKApoptosisAutophagyhuman dental pulp stem cellsestrogen receptor βRunx2acetylcholinesteraseosteoporosisMC3T3-E1 cellsPC12 cellsBeclin1choline acetyltransferaseP38 mitogen-activated protein kinaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Neoeriocitrin
Cat. No.:
HY-N4119
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.